At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 557 enrolled
Drug / intervention
Erenumab +1 morebiological
Likely dose
Erenumab 70 mg subcutaneously once monthlyAI-extracted
Key inclusion· 3
- ✓History of at least 5 migraine attacks
- ✓≥15 headache days during baseline period, with ≥8 days meeting migraine criteria
- ✓≥80% diary compliance during baseline period
Key exclusion· 5
- ✕Migraine onset after age 50
- ✕History of cluster headache or hemiplegic headache
- ✕Evidence of seizure disorder or major psychiatric disorder
- ✕Cardiac disease or active hepatic disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients
In Brief
A Phase 3 clinical trial evaluating Erenumab and Placebo for Migraine. Completed, enrolled 557 participants across 63 sites in 9 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesChina, India, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartAug 2019
Primary CompletionAug 2021
Study CompletionApr 2024
TodayJul 2026
First PostedMar 7, 2019
Enrollment StartAug 26, 2019
Primary CompletionAug 11, 2021
Study CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.3 years ago
Interventions
Erenumabbiological
Administered by pre-filled syringe
Placeboother
Administered by pre-filled syringe